Roche (OTCQX:RHHBY) announces positive results from a Phase 3 clinical trial, ARCHWAY,
evaluating its Port Delivery System (PDS) with ranibizumab in patients
with neovascular age-related macular degeneration (wet AMD).
The study met the primary endpoint demonstrating
that patients with PDS who received refills every six months achieved
equivalent improvements in visual acuity compared to patients receiving
monthly ranibizumab 0.5 mg injections.
On the safety front, PDS was generally well-tolerated with a favorable benefit-risk profile.
PDS is a permanent refillable eye implant about
the size of a grain of rice that continuously delivers a customized
formulation of ranibizumab over a period of months.
The company markets the injectable formulation of ranibizumab as Lucentis.
Complete results will be presented at an upcoming
medical conference and submitted to global health authorities for
potential approval.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.